- Home
- ITOC vs ERNA Comparison
ITOC vs ERNA Comparison
Compare ITOC & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITOC | ERNA |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 5.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ITOC | ERNA |
|---|---|---|
| Price | $0.34 | $4.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 401.5K | 395.3K |
| Earning Date | 03-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.13 |
| 52 Week High | $0.65 | $3.93 |
Technical Indicators
Market Signals| Indicator | ITOC | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 97.45 |
| Support Level | $0.29 | $1.13 |
| Resistance Level | $0.36 | N/A |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.00 | 0.38 |
| Stochastic Oscillator | 26.63 | 93.73 |
Price Performance
Historical ComparisonAbout ITOC iTonic Holdings Ltd Class A Ordinary Shares
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.